Business Wire

Scientist.com Announces Fourth Podcast in Mendelspod Series on Human Biospecimen Quality and Regulations

Share

Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced the successful conclusion of a four-part podcast series on human biological samples and biobanking. The four guests offered thoughtful insights and ideas from an academic, pharmaceutical and small business perspective. The episodes were hosted by Mendelspod, one of the life science industry’s leading podcasts.

“This is the second time we’ve covered human biospecimen quality and governance on this show, which tells me that people are interested and looking for answers,” said Theral Timpson, Host, Producer and Co-Founder of Mendelspod. “What Scientist.com is doing—offering a self-regulatory solution within the life sciences—is a practical first step toward filling an important gap.”

The series featured experts in biospecimen regulation, biobanking and compliance, including Carolyn Compton, PhD, Chief Medical Officer of the National Biomarker Development Alliance and ASU professor; Shannon McCall, PhD, Director of the Precision Cancer Medicine Initiative at the Biorepository and Precision Pathology Center at Duke University; Kirstin Goldring, PhD, Counselor at the European Society for Biopreservation and Biobanking and member of ISBER; and Matt McLoughlin, Vice President of Compliance at Scientist.com. Topics covered ranged from the sustainability of biobanks to a discussion of COMPLi™—Scientist.com’s proprietary compliance framework for overseeing the acquisition of human biological samples for research.

“It was an honor to be included amongst a group of such distinguished and knowledgeable speakers on the topic of human biospecimen quality and biobanking,” commented McLoughlin. “Forums like these raise awareness regarding the sustainability of biobanks and help us create a more standardized set of rules governing human biospecimen acquisition.”

All podcasts are accessible free of charge at https://mendelspod.com/.

About Scientist.com

Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo, among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

Contact information

Media Contact:
Scientist.com
Sean Preci
Director of Communications
+1 858-455-1300, ext. 401
marketing@scientist.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump5.6.2020 13:00:00 CESTPress release

Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous coronary intervention (PCI) patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005049/en/ FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump Impella ECP is the world’s smallest heart pump. It achieves peak flows greater than 3.5 L/min and is delivered though a slender-profile sheath. It is un-sheathed in the descending aorta and expands to approximately 18 Fr. Using a specially designed pigtail, it crosses the aortic valve without a wire, and pumps from inside the ventricle. When the procedure is complete, the pump is

Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!5.6.2020 11:10:00 CESTPress release

Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value. As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service. “Datalytyx said they could

Pegasus Development AG: Green Light for Multiple Production Sites Worldwide5.6.2020 09:27:00 CESTPress release

Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastril-Nuevo production facilities. New production facilities will be set up at several locations across the world and the site in Turkey is being expanded. These investments will also create new jobs. The takeover and expansion of the following production facilities are planned in all 20 countries of Latin America, as well as France, Spain, Portugal, Greece, Cyprus, Nigeria, Ethiopia, Uganda, Tanzania, Mozambique, Angola, Mauritius, Guinea-Bissau, Cape Verde, São Tome, and Mongolia. The demand for disinfectants has skyrocketed as a result of the coronavirus. Especially high revenues are expected from products which are based on vegetable surfactants and are alcohol-free, such as Nuevo. This was the decisive factor in the management's decision to further expand the quantity and range of Nuevo pro

In COVID-19, Pudu Robotics Provides Non-contact Delivery Service in Hundreds of Hospitals Worldwide5.6.2020 09:00:00 CESTPress release

During COVID-19, hundreds of Pudu Robotics’ robot Pudubot is offering delivery service in hospitals worldwide. This non-contact delivery service by Pudubot helps avoid the spread of virus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005095/en/ (Photo: Business Wire) After the outbreak of COVID-19, the pandemic with the characteristic of human-to-human transmission, a large number of hospitals and restaurants are seeking help from Pudu Robotics out of an urgent need for non-contact delivery. Pudu Robotics responded positively by devoting robots to several hospitals in Seoul, South Korea, Beijing, China, Wuhan, China and so on. Because Pudu Robotics’ robots are fully automatic, they can achieve the delivery process all by themselves, which reduces contact between people and effectively prevents the spread of the virus. Pudubot is equipped with multi-sensor and positioning and navigation technology. With large-capacity

IDEMIA and BBVA Partner to Launch Spain’s First Payment Card Made of Recycled PVC5.6.2020 09:00:00 CESTPress release

IDEMIA, the global leader in Augmented Identity, is supplying the very first cards made out of recycled plastics in Spain to BBVA. The bank will first distribute the cards to their Spanish customers with a BBVA Youth Account in June 2020. This new payment card is a strong commitment from BBVA to contributing to the United Nations Sustainable Development Goals for the fight against climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005037/en/ (Graphic: Business Wire) Each year, approximately 6 billion plastic payment cards are produced according to the 2018 Nilson Report1. In the context of the United Nations Sustainable Development Goals and the Paris Agreement, IDEMIA’s cutting-edge technology has been selected by BBVA, one of the largest banks in Spain, to migrate part of its existing first-use PVC cards to innovative recycled PVC cards. By the end of the year BBVA will enable more than half a million Spa

EIT Digital: Strengthening European Digital Infrastructure and Data Sovereignty5.6.2020 06:00:00 CESTPress release

Recent discussions around access to 5G technology and COVID-19 contact tracing apps highlight the need for European digital sovereignty. In its latest policy perspective report on ‘European Digital Infrastructure- and Data Sovereignty’, EIT Digital offers a concrete scenario-based framework for digital policy development. The study provides an overview of policy motivations, trends, instruments, and the roles of various actors in defining the perception of and perspectives for Europe’s digital sovereignty. “What becomes clear is that we need coordinated action between the policy shapers at European and national levels and the makers from business and industry to create a sovereign European digital reality. Key are policies that enhance innovation and respect European values and rights while creating equal economic opportunity for all actors,” says EIT Digital CEO Willem Jonker. EIT Digital collaborated with the Digital Enlightenment Forum to execute the report. The study supports the d